ArticleCase reports in oncology

Pembrolizumab plus Lenvatinib for Synchronous Triple Primary Malignancies of the Kidney, Bladder, and Liver: Clinical Implications of Conflict of Drug Doses and Dominant Tumor Biology.

Yuichiro Atagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.